摘要
乳腺癌作为一种常见的女性恶性肿瘤,其高发人群主要为绝经前女性。乳腺癌的诱发因素包括未婚、未孕、晚育、未哺乳、长期服用外源性雌激素、患乳腺良性疾病未及时就诊、乳腺癌家族病史等,其中乳腺癌家族病史是最主要的诱发因素。近年来,乳腺癌在青年女性中的发病率呈上升趋势,且乳腺癌患者的病理特征更具有侵袭性,治愈率较低,死亡率长期僵持不下,临床治疗效果也不尽如人意。随着医疗技术的不断改善以及对乳腺癌治疗方法的进一步关注,托瑞米芬在乳腺癌治疗中应用日渐广泛。托瑞米芬的耐药性较强、服用后患者发生不良反应的概率较小、治疗效果好,目前已成为治疗乳腺癌的关键药物。
Breast cancer is a common malignant tumor for women, premenopausal women would be at high risk of breast cancer. The inducing factors of breast cancer is varied, including an unmarried, no pregnancy, late pregnancy, no lactation, long-term use of exogenous estrogen, no timely treatment for breast benign disease, and family history of breast cancer. Among them, family history of breast cancer is one of the most important causes for breast cancer. In recent years, the incidence of breast cancer in young women showed a rising trend, the research also showed that the pathological of breast cancer in patients is more aggressive. The cure rate is low, the mortality is high for a long time, and the clinical treatment practice effect of patients with breast cancer is not satisfactory. As the medical technology got ceaseless im-provement, toremifene was used for the treatment of breast cancer. Toremifene resistance is stronger, the probability of occurrence of adverse reactions is smaller, and the treatment effect is good. For now, it has become a key drug for the treatment of breast cancer patients.
作者
梁法清
何阳君
杜正贵
LIANG Faqing;HE Yangjun;DU Zhenggui(Department of Thyroid Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610091, China;Chengdu Seventh People’ s Hospital, Chengdu, Sichuan, 61041, China)
出处
《肿瘤药学》
CAS
2018年第2期139-142,共4页
Anti-Tumor Pharmacy
基金
四川省科技厅项目(2015SZ0236)
关键词
乳腺癌
托瑞米芬
研究进展
病理特征
Breast cancer
Toremifene
Research progress
Pathological features
